Skip to main content
JW PHARMACEUTICAL logo

JW PHARMACEUTICAL — Investor Relations & Filings

Ticker · 001060 ISIN · KR7001060003 KO Manufacturing
Open in API
Filings indexed 310 across all filing types
Latest filing 2020-02-04 Director's Dealing
Country KR South Korea
Listing KO 001060

About JW PHARMACEUTICAL

https://www.jw-pharma.co.kr/pharma/en/m…

JW Pharmaceutical is a company focused on the research, development, and commercialization of pharmaceutical products. It provides a broad portfolio of therapeutic drugs, including specialty medicines and over-the-counter (OTC) solutions. Key product areas include nutritional infusions (Combiflex®, Winuf®), treatments for neutropenia (Neutrogin®), and cardiovascular medicines (Livalo®). Its consumer healthcare offerings feature the Hi-mom® brand of advanced wound care products. The company emphasizes innovation, advancing a pipeline of new drugs targeting oncology and immune diseases. This research is driven by proprietary technology platforms and includes candidates such as the gout treatment Epaminurad.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service in South Korea. This type of filing is a mandatory disclosure by company insiders (directors/executives) regarding their personal shareholdings and changes therein. In the provided classification schema, reports of personal share transactions by company directors and executives are categorized as 'Director's Dealing'.
2020-02-04 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (DART system) used by corporate insiders to disclose their shareholdings and changes therein. This corresponds to the 'Director's Dealing' category, which covers personal share transactions by company directors and executives.
2020-02-04 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service in South Korea. This document details the share ownership and changes in holdings by a specific executive (Park Young-geun) of JW Pharmaceutical. According to the provided definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing' (DIRS).
2020-02-04 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (DART system) used by company insiders (executives/directors) to disclose their personal shareholdings and changes therein. This corresponds to the 'Director's Dealing' category, which covers insider trades and ownership reports by company executives.
2020-01-08 Korean
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Capital/Financing Update Classification · 95% confidence The document is a formal regulatory filing from JW Pharmaceutical regarding the adjustment of conversion prices for convertible preferred shares due to a bonus issue (free capital increase). This type of disclosure, which details changes to the terms of convertible securities, falls under the category of capital structure and financing updates. It is not a report publication announcement, but rather a direct disclosure of a corporate action affecting capital instruments.
2019-12-31 Korean
주요사항보고서(무상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) from JW Pharmaceutical regarding a 'Bonus Issue' (무상증자결정). A bonus issue is a corporate action that changes the company's capital structure by issuing new shares to existing shareholders without additional cost. According to the provided filing definitions, announcements regarding new share issues or capital changes fall under the 'Share Issue/Capital Change' (SHA) category.
2019-12-16 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.